Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Abdominal aortic aneurysms in primary care
Risk-stratified screening and prophylaxis
- Cardiology
Minimally invasive – the quiet triumph of modern heart surgery
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Age-related neurocognitive disorders
Neuroprotective effects of Ginkgo biloba extract
How origin and place of residence promote CF-associated diabetes
- Patients with leg swelling
DVT and other common DDs with peripheral edema
- Pancreatic Cancer
Innovative early detection with a focus on liquid biopsy and AI
- Cervical Cancer